CJC-1295
Also known as: GRF 1-29 (CJC1295)
CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analog studied in laboratory research for growth-hormone release and recovery. It is a research compound and is not approved by the FDA for human use.
What is CJC-1295?
CJC-1295 is a long-acting growth-hormone-releasing hormone (GHRH) analog. CJC-1295 functions as a long-acting analog of growth hormone-releasing hormone (GHRH), stimulating the secretion of growth hormone (GH) from the pituitary gland. This increased GH secretion subsequently elevates insulin-like growth factor I (IGF-I) levels, with both hormones exhibiting sustained, dose-dependent elevations following administration. The mechanism involves CJC-1295's pharmacokinetic profile that promotes prolonged stimulation of the GH/IGF-I axis, supporting tissue growth and regeneration processes.
It is best referenced by its chemistry (PubChem CID 91971820, molecular formula C165H269N47O46). CJC-1295 is sold and discussed for laboratory and research use only.
Key Benefits & Mechanisms
Mechanism of action
CJC-1295 functions as a long-acting analog of growth hormone-releasing hormone (GHRH), stimulating the secretion of growth hormone (GH) from the pituitary gland. This increased GH secretion subsequently elevates insulin-like growth factor I (IGF-I) levels, with both hormones exhibiting sustained, dose-dependent elevations following administration. The mechanism involves CJC-1295's pharmacokinetic profile that promotes prolonged stimulation of the GH/IGF-I axis, supporting tissue growth and regeneration processes.
Research Summary
CJC-1295 has been examined in peer-reviewed research; representative studies are listed below. The publicly available evidence is primarily preclinical, and CJC-1295 is not approved by the FDA for human use.
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. (2006) PubMed · PMID 16352683
- Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. (2026) PubMed · PMID 41490200
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. (2026) PubMed · PMID 41476424
Frequently asked questions about CJC-1295
Is CJC-1295 FDA approved?
No. CJC-1295 is not approved by the FDA for human use. It is sold for laboratory and research purposes only, and its public evidence base is primarily preclinical.
What is CJC-1295 studied for?
In research, CJC-1295 is studied for growth-hormone release and recovery. CJC-1295 functions as a long-acting analog of growth hormone-releasing hormone (GHRH), stimulating the secretion of growth hormone (GH) from the pituitary gland. This increased GH secretion subsequently elevates insulin-like growth factor I (IGF-I) levels, with both hormones exhibiting sustained, dose-dependent elevations following administration. The mechanism involves CJC-1295's pharmacokinetic profile that promotes prolonged stimulation of the GH/IGF-I axis, supporting tissue growth and regeneration processes.
How is CJC-1295 stored?
Like most peptides, lyophilized CJC-1295 is best kept cold, dark, and dry; reconstituted material is refrigerated and used within a limited window. See the storage and reconstitution guide for details.
Legal & research status: Research use only — not approved by the FDA for human use. Sold and discussed for laboratory and research use only, not for human consumption.